The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 26, 2019

Filed:

May. 31, 2016
Applicant:

Korea Institute of Science and Technology, Seoul, KR;

Inventors:

Kwangmeyung Kim, Seoul, KR;

Ju Hee Ryu, Seoul, KR;

Ick Chan Kwon, Seoul, KR;

Man Kyu Shim, Seoul, KR;

Hong Yeol Yoon, Seoul, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 51/00 (2006.01); A61M 36/14 (2006.01); A61K 49/00 (2006.01); C07K 9/00 (2006.01); G01N 33/574 (2006.01); G01N 33/58 (2006.01); C07K 5/11 (2006.01); C07K 5/107 (2006.01); A61K 47/54 (2017.01);
U.S. Cl.
CPC ...
A61K 49/0056 (2013.01); A61K 47/555 (2017.08); A61K 49/0032 (2013.01); A61K 49/0052 (2013.01); C07K 5/1016 (2013.01); C07K 5/1019 (2013.01); C07K 9/001 (2013.01); G01N 33/57496 (2013.01); G01N 33/581 (2013.01); G01N 2333/96466 (2013.01);
Abstract

The present disclosure relates to a glycopeptide targeting cancer cells and a contrast agent kit containing the same. The glycopeptide is one wherein an azide reporting monosaccharide is bound to a substrate peptide. As the substrate peptide is specifically cleaved by cathepsin B in cancer cells, an azide reporting monosaccharide is expressed onto the cell surface via metabolic glycoengineering, thereby providing a target for action as a contrast agent. Accordingly, because the azide is exposed to the cell surface only by cathepsin B, as it is specifically expressed in cancer cells, in particular in metastatic cancer cells, while it is limitedly expressed in normal cells and is hardly excreted out the cells, the cancer cells can be selectively imaged by an azide-specific contrast agent.


Find Patent Forward Citations

Loading…